On March 27, 2024, Seelos Therapeutics, Inc. entered into Amendment No. 5 to its Convertible Promissory Note with Lind Global Asset Management V, LLC. This amendment adjusted the initial principal amount of the note, which was originally issued on November 23, 2021, and subsequently amended on four occasions. The latest amendment increased the outstanding principal amount by $1,492,844, bringing the total to $13,435,599. Additionally, the amendment outlined conditions regarding the company's cash balance requirements, share issuance in connection with the note's repayment or conversion, and a forbearance agreement by the holder on asserting any Material Adverse Effect claims until April 29, 2024. Seelos Therapeutics also committed to seeking stockholder approval for share issuance related to the note's conversion at a stockholder meeting to be held by July 31, 2024. The details of the amendment are fully disclosed in Exhibit 4.1 attached to the Form 8-K filed with the SEC.

On March 27, 2024, Seelos Therapeutics, Inc. entered into Amendment No. 5 to its Convertible Promissory Note with Lind Global Asset Management V, LLC. This amendment adjusted the initial principal amount of the note, which was originally issued on November 23, 2021, and subsequently amended on four occasions. The latest amendment increased the outstanding principal amount by $1,492,844, bringing the total to $13,435,599. Additionally, the amendment outlined conditions regarding the company's cash balance requirements, share issuance in connection with the note's repayment or conversion, and a forbearance agreement by the holder on asserting any Material Adverse Effect claims until April 29, 2024. Seelos Therapeutics also committed to seeking stockholder approval for share issuance related to the note's conversion at a stockholder meeting to be held by July 31, 2024. The details of the amendment are fully disclosed in Exhibit 4.1 attached to the Form 8-K filed with the SEC.